{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:15:58Z","timestamp":1793423758374,"version":"4.5.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Trauma Acute Care Surg"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>The genomic\/cytokine \u201cstorm\u201d after severe trauma is well described. However, the differing composition, magnitude and resolution of this response, and its relationship to clinical outcomes remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This is a secondary analysis of a prospective longitudinal cohort study of severely injured trauma patients in hemorrhagic shock. Peripheral blood sampling was performed at 0.5, 1, 4, 7, 14, and 28 days after injury for measurement of circulating immune biomarkers. K-means clustering using overall mean and trajectory slope of selected immunologic biomarkers were used to identify distinct temporal immunologic endotypes. Endotypes were compared with known clinical trajectories defined as early death (&lt;14 days), chronic critical illness (CCI) (ICU length of stay of \u226514 days with persistent organ dysfunction), and rapid recovery (RAP) (ICU length of stay of &lt;14 days with organ recovery).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      The cohort included 102 subjects enrolled across 2 level 1 trauma centers. We identified three distinct immunologic endotypes (\n                      <jats:italic toggle=\"yes\">i<\/jats:italic>\n                      A,\n                      <jats:italic toggle=\"yes\">i<\/jats:italic>\n                      B, and\n                      <jats:italic toggle=\"yes\">i<\/jats:italic>\n                      C), each with unique associations to clinical trajectory. Endotype\n                      <jats:italic toggle=\"yes\">i<\/jats:italic>\n                      A (n = 47) exhibited a moderate initial proinflammatory response followed by a return to immunologic homeostasis, with a primary clinical trajectory of RAP (n = 44, 93.6%). Endotype\n                      <jats:italic toggle=\"yes\">i<\/jats:italic>\n                      B (n = 44) exhibited an early hyperinflammatory response with persistent inflammation and immunosuppression, with the highest incidence of CCI (n = 10, 22.7%). Endotype\n                      <jats:italic toggle=\"yes\">i<\/jats:italic>\n                      C (n = 11) exhibited a similar hyperinflammatory response, but with rapid return to immunologic homeostasis and a predominant trajectory of RAP (n = 9, 81.8%). Patients with endotype\n                      <jats:italic toggle=\"yes\">i<\/jats:italic>\n                      B had the highest severity\/duration of organ dysfunction and highest incidence of nosocomial infections (50%,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.001), and endotype\n                      <jats:italic toggle=\"yes\">i<\/jats:italic>\n                      B was the predominant endotype of patients who developed CCI (10 of 13 patients, 76.9%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>\n                      We identified three distinct immunologic endotypes after severe injury differing the magnitude and duration of the early response. The clinical trajectory of CCI is characterized by an endotype (\n                      <jats:italic toggle=\"yes\">i<\/jats:italic>\n                      B) defined by persistent alteration in inflammation\/immunosuppression and is associated with poor clinical outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LEVEL OF EVIDENCE<\/jats:title>\n                    <jats:p>Prognostic, level III.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ta.0000000000003029","type":"journal-article","created":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:22:19Z","timestamp":1605918139000},"page":"257-267","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":39,"title":["Distinct immunologic endotypes are associated with clinical trajectory after severe blunt trauma and hemorrhagic shock"],"prefix":"10.1097","volume":"90","author":[{"given":"Scott C.","family":"Brakenridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongkai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dijoia","family":"Darden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Ghita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babette","family":"Brumback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Cuschieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald V.","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick A.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia M.","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Efron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyle L.","family":"Moldawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"issue":"7","key":"bib1-20250806","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.injury.2016.04.002","article-title":"Traumatic injury in the United States: in-patient epidemiology 2000\u20132011","volume":"47","year":"2016","journal-title":"Injury"},{"issue":"5","key":"bib2-20250806","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jama.2015.12","article-title":"Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial","volume":"313","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"bib3-20250806","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/SLA.0b013e31824f1ebc","article-title":"Benchmarking outcomes in the critically injured trauma patient and the effect of implementing standard operating procedures","volume":"255","year":"2012","journal-title":"Ann Surg"},{"issue":"5","key":"bib4-20250806","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/archsurg.140.5.432","article-title":"A 12-year prospective study of postinjury multiple organ failure: has anything changed?","volume":"140","year":"2005","journal-title":"Arch Surg"},{"issue":"12","key":"bib5-20250806","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1097\/CCM.0000000000002697","article-title":"The epidemiology of chronic critical illness after severe traumatic injury at two level-one trauma centers","volume":"45","year":"2017","journal-title":"Crit Care Med"},{"issue":"10","key":"bib6-20250806","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jama.2011.259","article-title":"Long-term survival of adult trauma patients","volume":"305","year":"2011","journal-title":"JAMA"},{"issue":"13","key":"bib7-20250806","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1084\/jem.20111354","article-title":"A genomic storm in critically injured humans","volume":"208","year":"2011","journal-title":"J Exp Med"},{"issue":"4","key":"bib8-20250806","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/CCM.0b013e3182376e9f","article-title":"The changing pattern and implications of multiple organ failure after blunt injury with hemorrhagic shock","volume":"40","year":"2012","journal-title":"Crit Care Med"},{"issue":"4","key":"bib9-20250806","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/SHK.0b013e3181d8e687","article-title":"Early elevation in random plasma IL-6 after severe injury is associated with development of organ failure","volume":"34","year":"2010","journal-title":"Shock"},{"issue":"5","key":"bib10-20250806","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/CCM.0b013e318277131c","article-title":"Development of a genomic metric that can be rapidly used to predict clinical outcome in severely injured trauma patients","volume":"41","year":"2013","journal-title":"Crit Care Med"},{"issue":"5","key":"bib11-20250806","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/SLA.0000000000003204","article-title":"Prospective validation of a transcriptomic metric in severe trauma","volume":"271","year":"2020","journal-title":"Ann Surg"},{"issue":"4","key":"bib12-20250806","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1172\/JCI124611","article-title":"Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases","volume":"129","year":"2019","journal-title":"J Clin Invest"},{"issue":"10","key":"bib13-20250806","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2213-2600(17)30294-1","article-title":"Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study","volume":"5","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"8","key":"bib14-20250806","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1164\/rccm.201807-1419OC","article-title":"Transcriptomic signatures in sepsis and a differential response to steroids. From the VANISH randomized trial","volume":"199","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"bib15-20250806","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/j.1541-0420.2007.00784.x","article-title":"Determining the number of clusters using the weighted gap statistic","volume":"63","year":"2007","journal-title":"Biometrics"},{"issue":"4","key":"bib16-20250806","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/TA.0000000000000568","article-title":"Genomics of injury: the Glue Grant experience","volume":"78","year":"2015","journal-title":"J Trauma Acute Care Surg"},{"issue":"6","key":"bib17-20250806","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1097\/TA.0b013e318256e000","article-title":"Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care","volume":"72","year":"2012","journal-title":"J Trauma Acute Care Surg"},{"issue":"23","key":"bib18-20250806","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1001\/jama.1994.03510470040032","article-title":"Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group","volume":"271","year":"1994","journal-title":"JAMA"},{"issue":"7","key":"bib19-20250806","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/00003246-199707000-00010","article-title":"Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group","volume":"25","year":"1997","journal-title":"Crit Care Med"},{"issue":"22","key":"bib20-20250806","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","article-title":"Drotrecogin alfa (activated) in adults with septic shock","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"bib21-20250806","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jama.1995.03520360048038","article-title":"Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group","volume":"273","year":"1995","journal-title":"JAMA"},{"issue":"11","key":"bib22-20250806","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/jama.2013.2194","article-title":"Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial","volume":"309","year":"2013","journal-title":"JAMA"},{"issue":"8","key":"bib23-20250806","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1097\/CCM.0b013e3181e7c5c9","article-title":"A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis","volume":"38","year":"2010","journal-title":"Crit Care Med"},{"issue":"7","key":"bib24-20250806","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1164\/rccm.200903-0363OC","article-title":"Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial","volume":"180","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"bib25-20250806","doi-asserted-by":"crossref","first-page":"e2016485","DOI":"10.1001\/jamanetworkopen.2020.16485","article-title":"Association of interleukin 7 immunotherapy with lymphocyte counts among patients with severe coronavirus disease 2019 (COVID-19)","volume":"3","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"bib26-20250806","doi-asserted-by":"crossref","first-page":"e98960","DOI":"10.1172\/jci.insight.98960","article-title":"Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial","volume":"3","year":"2018","journal-title":"JCI Insight"},{"issue":"5","key":"bib27-20250806","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/CCM.0000000000003685","article-title":"Immune checkpoint inhibition in sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559)","volume":"47","year":"2019","journal-title":"Crit Care Med"},{"key":"bib28-20250806","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S2213-2600(20)30217-4","article-title":"Immunotherapies for COVID-19: lessons learned from sepsis","volume":"8","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"bib29-20250806","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1056\/NEJMcibr1004371","article-title":"Immunotherapy for sepsis\u2013a new approach against an ancient foe","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"bib30-20250806","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMcibr1404664","article-title":"Parallels between cancer and infectious disease","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"bib31-20250806","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3389\/fimmu.2018.00595","article-title":"Innate immunity in the persistent inflammation, immunosuppression, and catabolism syndrome and its implications for therapy","volume":"9","year":"2018","journal-title":"Front Immunol"},{"issue":"2","key":"bib32-20250806","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/CCM.0000000000002074","article-title":"Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome","volume":"45","year":"2017","journal-title":"Crit Care Med"},{"issue":"2","key":"bib33-20250806","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/TA.0000000000001758","article-title":"Benchmarking clinical outcomes and the immunocatabolic phenotype of chronic critical illness after sepsis in surgical intensive care unit patients","volume":"84","year":"2018","journal-title":"J Trauma Acute Care Surg"},{"key":"bib34-20250806","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3389\/fimmu.2018.01511","article-title":"Chronic critical illness and the persistent inflammation, immunosuppression, and catabolism syndrome","volume":"9","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"bib35-20250806","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/SLA.0000000000003458","article-title":"Current epidemiology of surgical sepsis: discordance between inpatient mortality and 1-year outcomes","volume":"270","year":"2019","journal-title":"Ann Surg"},{"issue":"4","key":"bib36-20250806","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/CCM.0000000000003655","article-title":"The development of chronic critical illness determines physical function, quality of life, and long-term survival among early survivors of sepsis in surgical ICUs","volume":"47","year":"2019","journal-title":"Crit Care Med"},{"issue":"2","key":"bib37-20250806","first-page":"299","article-title":"Early blood product and crystalloid volume resuscitation: risk association with multiple organ dysfunction after severe blunt traumatic injury","volume":"71","year":"2011","journal-title":"J Trauma"}],"container-title":["Journal of Trauma and Acute Care Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TA.0000000000003029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T16:19:50Z","timestamp":1754497190000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TA.0000000000003029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ta.0000000000003029","relation":{},"ISSN":["2163-0763","2163-0755"],"issn-type":[{"value":"2163-0763","type":"electronic"},{"value":"2163-0755","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,19]]}}}